PDX Pharmaceuticals, in collaboration with OHSU, has received a perfect score on its fast track SBIR grant application to the NCI. The application focuses on development of ARAC™ pipeline. Grant title: Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer, requested budget of $2.26 M over 3 years.
Furthermore, the team scored very high (18) on its direct phase II SBIR grant application to the NCI. The application focuses on IND enabling studies of AIRISE™ pipeline. Grant title: In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response, requested budget of $2.0 M over 1.5 years .
The current NCI-SBIR payline is 22 and below. Therefore, we anticipate both applications will be awarded (pending council review).
ARAC™ stands for Antigen Release Agent and Checkpoint Inhibitor
AIRISE™ stands for Augmenting Immune Responses and Inhibiting the Suppressive Environment of Tumors